Adenosine and adenosine receptors
Author(s)
Bibliographic Information
Adenosine and adenosine receptors
(Receptors)
Humana Press, c1990
Available at 1 libraries
  Aomori
  Iwate
  Miyagi
  Akita
  Yamagata
  Fukushima
  Ibaraki
  Tochigi
  Gunma
  Saitama
  Chiba
  Tokyo
  Kanagawa
  Niigata
  Toyama
  Ishikawa
  Fukui
  Yamanashi
  Nagano
  Gifu
  Shizuoka
  Aichi
  Mie
  Shiga
  Kyoto
  Osaka
  Hyogo
  Nara
  Wakayama
  Tottori
  Shimane
  Okayama
  Hiroshima
  Yamaguchi
  Tokushima
  Kagawa
  Ehime
  Kochi
  Fukuoka
  Saga
  Nagasaki
  Kumamoto
  Oita
  Miyazaki
  Kagoshima
  Okinawa
  Korea
  China
  Thailand
  United Kingdom
  Germany
  Switzerland
  France
  Belgium
  Netherlands
  Sweden
  Norway
  United States of America
Note
Includes bibliographical references and index
Description and Table of Contents
Description
Historically, the major emphasis on the study of purinergic systems has been predominantly in the areas of physiology and gross pharmacology. The last decade has seen an exponential in- crease in the number of publications related to the role of both adenosine and A TP in mammalian tissue function, a level of interest that has evolved from a more molecular focus on the identity of adenosine and A TP receptor subtypes and the search for selective ligands and development of radioligand binding assays by Fred Bruns and colleagues (especially that for A receptors) that played z a highly significant role in advancing research in the area. In the 60 years since adenosine was first shown to be a potent hypotensive agent, a considerable investment has been made by several pharmaceutical companies-including Abbott, Byk Gulden, Takeda, Warner-LambertlParke Davis, Boehringer Mann- heim, Boehringer Ingelheim, Nelson/Whitby Research and CffiA- Geigy-as well as John Daly's laboratory at the National Institutes of Health, to design new adenosine receptor ligands, and both agon- ists and antagonists with the aim of developing new therapeutic entiities.
Numerous research tools have derived from these efforts including: 2-chloroadenosine, R-PIA (~-phenylisopropyladeno- sine; NECA (5' N-ethylcarboxamidoadenosine); CV1808; CI936; PD 125,944; ~-benzyladenosine; PACPX; CPX; CPT; XAC; CGS 15943 and CGS 21680. Yet in the realm of therapeutics it was only in 1989 that adenosine itself was approved for human use in the treatment of supraventricular arrythmias.
Table of Contents
Historical Perspective. Adenosine Receptors: An Historical Perspective. Characterization of the Receptor and Its Binding Site. Radioligand Binding Assays for Adenosine Receptors. Structure-Activity Relationships of Adenosine A1 and A2 Receptors. Biochemical Mechanisms of Receptor Action. Signal Transduction Mechanisms for Adenosine. Electrophysiological Aspects of Adenosine Receptor Function. Adenosine Release. Adenosine Deaminase and [3H]Nitrobenzylthioinisine as Markers of Adenosine Metabolism and Transport in Central Purinergic Systems. Physiological Functions of Adenosine Receptors. Adenosine and Cardiovascular Function. Adenosine and Renal Function. The Role of Adenosine in Respiratory Physiology. Adenosine Central Nervous System Function. Receptor Regulation. Adenosine and Host Defense: Modulation through Metabolism and Receptor-Mediated Mechanisms. Future Vistas. Adenosine Receptors: Future Vistas. Index.
by "Nielsen BookData"